ALK and non-small cell lung carcinoma: Epidermal growth factor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors are some of the widely available targeted agents in non-small lung cancer (NSCLC), demonstrating dramatic clinical effects when compared to conventional cytotoxic chemotherapy.